Enhancement of the immunogenicity of an infectious laryngotracheitis virus DNA vaccine by a bicistronic plasmid encoding glycoprotein B and interleukin-18

2010 ◽  
Vol 87 (2) ◽  
pp. 235-241 ◽  
Author(s):  
Hong-Ying Chen ◽  
Li Zhao ◽  
Zhan-Yong Wei ◽  
Bao-An Cui ◽  
Zhen-Ya Wang ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Glycoprotein B ◽  
Interleukin 18 ◽  
Infectious Laryngotracheitis Virus ◽  
Infectious Laryngotracheitis ◽  
Laryngotracheitis Virus

Interleukin-18-mediated enhancement of the protective effect of an infectious laryngotracheitis virus glycoprotein B plasmid DNA vaccine in chickens

2011 ◽  
Vol 60 (1) ◽  
pp. 110-116 ◽  
Author(s):  
Hong-Ying Chen ◽  
Hong-Ying Zhang ◽  
Xin-Sheng Li ◽  
Bao-An Cui ◽  
Shu-Juan Wang ◽  
...  
Keyword(s):  
Dna Vaccine ◽  
Plasmid Dna ◽  
Glycoprotein B ◽  
Morbidity Rate ◽  
Interleukin 18 ◽  
T Helper 1 ◽  
Infectious Laryngotracheitis Virus ◽  
Plasmid Dna Vaccine ◽  
Infectious Laryngotracheitis ◽  
Laryngotracheitis Virus

The immunogenicity of an infectious laryngotracheitis virus (ILTV) glycoprotein B (gB) plasmid DNA vaccine and the immunoregulatory activity of chicken interleukin-18 (IL-18) were investigated in a challenge model. Two recombinant plasmids, pcDNA3.1/gB (pgB) and pcDNA3.1/IL-18 (pIL-18), containing gB and IL-18 were constructed. Chickens were intramuscularly administered two immunizations 2 weeks apart, and challenged with the virulent CG strain of ILTV 2 weeks later. All animals vaccinated with pgB alone or with a combination of pgB plus pIL-18 developed a specific anti-ILTV ELISA antibody and splenocyte proliferation response. The ratios of CD4+ to CD8+ T lymphocytes in chickens immunized with pgB plus pIL-18 were significantly higher than in those immunized with pgB alone. Co-injection of pIL-18 significantly increased the production of gamma interferon and IL-2, indicating that IL-18 enhances the T helper 1-dominant immune response. Challenge experiments showed that the morbidity rate in the pgB group (25 %) was significantly higher than that in the pgB plus pIL-18 group (10 %). The mortality rates in the pgB and pgB plus pIL-18 groups were 10 and 0 %, respectively, and the corresponding protection rates were 60 and 80 %. These results indicate that IL-18 may be an effective adjuvant for an ILTV vaccine.

Nucleotide sequence of the gene encoding infectious laryngotracheitis virus glycoprotein B

Virology ◽  
1991 ◽  
Vol 184 (1) ◽  
pp. 404-410 ◽  
Author(s):  
Kritaya Kongsuwan ◽  
C.T. Prideaux ◽  
M.A. Johnson ◽  
M. Sheppard ◽  
K.J. Fahey
Keyword(s):  
Nucleotide Sequence ◽  
Glycoprotein B ◽  
Infectious Laryngotracheitis Virus ◽  
Gene Encoding ◽  
Virus Glycoprotein ◽  
Infectious Laryngotracheitis ◽  
Laryngotracheitis Virus

scholarly journals Immunoinformatics Approach for Multiepitopes Vaccine Prediction against Glycoprotein B of Avian Infectious Laryngotracheitis Virus

2019 ◽  
Vol 2019 ◽  
pp. 1-23 ◽  
Author(s):  
Sumaia A. Ali ◽  
Yassir A. Almofti ◽  
Khoubieb A. Abd-elrahman
Keyword(s):  
B Cell ◽  
Glycoprotein B ◽  
Economic Losses ◽  
Upper Respiratory Tract ◽  
Infectious Laryngotracheitis Virus ◽  
B Cell Epitopes ◽  
Mhc Ii ◽  
High Affinity ◽  
Infectious Laryngotracheitis ◽  
Laryngotracheitis Virus

Infectious laryngotracheitis virus (ILTV) is a gallid herpesvirus type 1, a member of the genus Iltovirus. It causes an infection in the upper respiratory tract mainly trachea which results in significant economic losses in the poultry industry worldwide. Vaccination against ILTV produced latent infected carriers’ birds, which become a source of virus transmission to nonvaccinated flocks. Thus this study aimed to design safe multiepitopes vaccine against glycoprotein B of ILT virus using immunoinformatic tools. Forty-four sequences of complete envelope glycoprotein B were retrieved from GenBank of National Center for Biotechnology Information (NCBI) and aligned for conservancy by multiple sequence alignment (MSA). Immune Epitope Database (IEDB) analysis resources were used to predict and analyze candidate epitopes that could act as a promising peptide vaccine. For B cell epitopes, thirty-one linear epitopes were predicted using Bepipred. However eight epitopes were found to be on both surface and antigenic epitopes using Emini surface accessibility and antigenicity, respectively. Three epitopes (190KKLP193, 386YSSTHVRS393, and 317KESV320) were proposed as B cell epitopes. For T cells several epitopes were interacted with MHC class I with high affinity and specificity, but the best recognized epitopes were 118YVFNVTLYY126, 335VSYKNSYHF343, and 622YLLYEDYTF630. MHC-II binding epitopes, 301FLTDEQFTI309,277FLEIANYQV285, and 743IASFLSNPF751, were proposed as promising epitopes due to their high affinity for MHC-II molecules. Moreover the docked ligand epitopes from MHC-1 molecule exhibited high binding affinity with the receptors; BF chicken alleles (BF2 2101 and 0401) expressed by the lower global energy of the molecules. In this study nine epitopes were predicted as promising vaccine candidate against ILTV. In vivo and in vitro studies are required to support the effectiveness of these predicted epitopes as a multipeptide vaccine through clinical trials.

Sign in / Sign up

Export Citation Format

Share Document